Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE

This article was originally published in The Pink Sheet Daily

Executive Summary

Strength of Novartis’ new heart failure drug Entresto contrasts with yet another failed outcomes study for its old renin inhibitor Tekturna.

You may also be interested in...



Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC

Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.

With Its Hypertension Franchise in Crisis, Novartis Restructures

Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.

Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis

Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel